Skip to main content
Download PDF

Costunolide causes mitotic arrest and enhances radiosensitivity in human hepatocellular carcinoma cells

Radiation Oncology volume 6, Article number: 56 (2011) Cite this article

Abstract

Purpose

This work aimed to investigate the effect of costunolide, a sesquiterpene lactone isolated from Michelia compressa, on cell cycle distribution and radiosensitivity of human hepatocellular carcinoma (HCC) cells.

Methods

The assessment used in this study included: cell viability assay, cell cycle analysis by DNA histogram, expression of phosphorylated histone H3 (Ser 10) by flow cytometer, mitotic index by Liu's stain and morphological observation, mitotic spindle alignment by immunofluorescence of alpha-tubulin, expression of cell cycle-related proteins by Western blotting, and radiation survival by clonogenic assay.

Results

Our results show that costunolide reduced the viability of HA22T/VGH cells. It caused a rapid G2/M arrest at 4 hours shown by DNA histogram. The increase in phosphorylated histone H3 (Ser 10)-positive cells and mitotic index indicates costunolide-treated cells are arrested at mitosis, not G2, phase. Immunofluorescence of alpha-tubulin for spindle formation further demonstrated these cells are halted at metaphase. Costunolide up-regulated the expression of phosphorylated Chk2 (Thr 68), phosphorylated Cdc25c (Ser 216), phosphorylated Cdk1 (Tyr 15) and cyclin B1 in HA22T/VGH cells. At optimal condition causing mitotic arrest, costunolide sensitized HA22T/VGH HCC cells to ionizing radiation with sensitizer enhancement ratio up to 1.9.

Conclusions

Costunolide could reduce the viability and arrest cell cycling at mitosis in hepatoma cells. Logical exploration of this mitosis-arresting activity for cancer therapeutics shows costunolide enhanced the killing effect of radiotherapy against human HCC cells.

Background

Costunolide is a sesquiterpene lactone isolated from Michelia compressa in our previous work [1]. Michelia compressa is a common origin of wooden furniture used worldwide. Costunolide has been also identified in several species of plants, including Saussurea lappa C.B. Clarke [2], Aucklandia lappa Decne [3], Laurus nobilis [4], Magnolia grandiflora [5] and Michelia floribunda [6]. Bocca et al reported that costunolide interfered with the microtubule proteins [7]. However, whether this activity refers to mitosis arrest and subsequent applications for cancer therapy, such as radiosensitizing effect, remains unclear.

The primary liver cancers, in which 85 - 90% are hepatocellular carcinoma (HCC), is the third most common cause of death worldwide [8]. Despite aggressive therapy, the 5-year survival rate of patients with primary liver cancer remains less than 10% [9]. This poor prognosis is due to high recurrent and metastatic rates even after use of current treatment modalities such as surgery [10, 11], trans-hepatic artery chemoembolzation (TACE) [12], radiofrequency ablation [13], radiotherapy (RT) [14], and multitarget tyrosine kinase inhibitors [15].

Among these treatment modalities, the role of RT, especially for unresectable HCC [16], is becoming important due to the development of advanced conformal techniques. The major organ at risk for irradiating hepatoma is the remaining normal liver containing normal hepatocytes. Although advanced conformal RT techniques could focus the radiation to hepatoma and reduce the dose to surrounding normal counterpart, the low tolerance of hepatocytes to radiation remains a limiting factor while attempting to escalate dose to the targeting tumor. Given that radiation dose is the only significant factor in predicting therapeutic effect of RT [17], development of novel radiosensitizers which would lower the necessary dose to eradicate hepatoma and thus cause less damages to normal liver is in great demand in clinical practice.

Because cells at G2/M phase, especially the M phase, are the most radiosensitive population, pharmacological agents possessing the microtubule-interfering activity have been shown as promising radiosensitizers. For example, taxane has been demonstrated as a radiosensitizer for treatment of non-small cell lung cancer [18, 19]. Since costunolide has been reported as a microtubule-interfering agent by Bocca et al and shown to cause G2/M-arresting in our preliminary work, this compound may function as a radiosensitizer. To prove this working hypothesis, we examined whether costunolide induced cell cycle arrest specifically at G2 or M phase, investigated involved signaling pathways and measured the radiosensitivity of costunolide-treated hepatoma cells in this study.

Methods

Preparation of costunolide and determination of purity

Costunolide was isolated from root wood of Michelia compressa as previously described [1]. It was dissolved in dimethylsulfoxide (DMSO). Costunolide was stored as stock solution at -20° C. The working solution was freshly prepared prior to use. In all cell culture experiments, the final concentration of DMSO did not exceed 0.1% (v/v) which has no influence on the cell growth.

Determination of drug purity

The samples were reconstituted with 100 mL methanol. The mobile phase was comprised of methanol and 10 mM sodium dihydrogen phosphate monohydrate in water (25:75, v/v, pH 6.5). The high performance liquid chromatography (HPLC) system was performed using a Shimadzu system (Shimadzu, Kyoto, Japan) consisting of a LC-20AT pump, a SIL-20AC auto-sampler, and an SPD-M20A detector. An Agilent extended-C18 column (4.6 × 150 mm, 5 μm) was used for separation (Merck, Germany). The UV absorbance at 204 nm wavelength was used for quantization. The retention time of costunolide was 6.31 minutes. Output data from the detector were integrated via a Class-VP 7.0 Client/Server Chromatography Data System (Shimadzu, Kyoto, Japan). Before subject to cell experiments, the purity of costunolide was examined. The optimum absorbance of costunolide is at 224 nm and the sample was inspected over a complete spectral range. Only one major peak can be seen in the HPLC analysis. According to the chromatogram, the purity of costunolide was approximately 99.9%.

Cell culture and viability assessment

The poorly differentiated human HCC cell line, HA22T/VGH, was kindly provided by Professor Hu (Veteran General Hospital, Taipei, Taiwan). It was cultured in DMEM (GIBCO, Grand Island, NY, USA) supplemented with NaHCO3 (10 mmol/L), HEPES (20 mmol/L) and 10% heat-inactivated fetal calf serum (FCS, Hyclone, Logan, UT, USA) in a humidified 5% CO2 incubator and maintained in an exponential growth state. To evaluate cell growth, the numbers of viable cells were counted on day 1, 2 and 3 by using trypan blue exclusion test. Adherent cells were collected by using 0.25% trypsin.

DNA histogram analysis

HA22T/VGH HCC cells were treated with 5 μM of costunolide for 0, 2, 4, 16 and 24 hours). Then the cells were harvested and washed with phosphate buffered saline (PBS), then fixed and permeated at 4°C for 1 hour with 70% ethanol. Cells were stained for 30 minutes with propidium iodide (PI) solution (PI, 0.5 mg/mL; RNAse, 0.1 mg/mL; Sigma) from a CycleTESTplus DNA reagent kit (Becton Dickinson, Lincoln Park, NJ, USA) in the dark. Analysis of DNA histogram was performed on a FACScaliber flow cytometer (Becton Dickinson, Lincoln Park, NJ, USA). The data from 104 cells were collected and analyzed using ModFit Software (Becton Dickinson, Lincoln Park, NJ, USA) to calculate the percentage of cells at G2/M phase.

Quantification of mitotic index

After treatment with 5 μM costunolide for 0, 4, 16 and 24 hours, HA22T/VGH HCC cells were collected and centrifuged onto a microscope slide using a Cytospin2 centrifuge (Shandon Inc., Pittsburgh, PA, USA). The slides were dried and cells were fixed with 4% paraformaldehyde in PBS (pH 7.4) and mounted in Vectashield mounting medium with 1.5 Ag/mL 4V, 6-diamidino-2-phenylindole (Vector Laboratories, Inc., Burlingame, CA). The cells were stained by method of Liu's stain as follows: cells were washed by PBS and fixed by cold methanol for 20 min. Liu A was added for 45 seconds at room temperature followed by adding Liu B for 90 seconds. Then cells were gently washed and the cell morphology was observed by light microscope. Light micrograph was taken using a microscope (Olympus, Tokyo, Japan) at a magnification of 400 or 1000. Photograph was taken with a digital camera (Olympus, Tokyo, Japan). Mitotic morphology was identified by appearance of duplicated chromatid pair aligned in the center of dividing cells. At least 200 cells per field in a minimum of five randomly selected fields were counted on three slides for each sample.

Detection of phosphorylated histone H3

The method for anti-phospho-histone H3 staining was performed and modified from a previous report [20]. In brief, growing cells were treated with 5 μM costunolide after 0, 2, 4, 16 and 24 hours. Then the HA22T/VGH HCC cells were trypsinized, fixed in 2% paraformaldehyd, permeablized with 1% Triton X-100 (Sigma), and stained with anti-phospho-histone 3 (Ser 10)-FITC (Cell Signaling, Danvers, MA, USA) at room temperature for 60 minutes. The cells were washed again with PBS and resuspended in PBS containing PI and RNase A. The samples were subjected to a FACScaliber flow cytometer and data analysis was done using CellQuest Pro software (Becton Dickinson, Lincoln Park, NJ, USA)

Immunofluorescence staining

After 5 μM costunolide treatment, the HA22T/VGH cells were plated on a 18 mm coverslip coated with 50 mg/mL of Poly-L-Lysine. Cells were incubated at 37 °C to allow attachment and spreading. For immunofluorescence staining, the cells were fixed with 3% formaldehyde for 10 minutes. Then the cells were washed with PBS, permeabilized with 0.5% Triton X-100, stained with primary antibody (a-tubulin 1: 50, Zymed laboratories Inc., South San Francisco, CA) for one hour. After washing with PBS, the bound mouse IgG was detected with Cy™2-conjugated anti-mouse antibody (1: 100, Jackson ImmunoResearch, West Groove, PA) and counterstained with 0.5 mg/mL of Hoechst 33342 (Sigma) in PBS for one hour. Images of stained cells were examined under a fluorescent microscope (ZEISS, Axioplan 2).

Western Blot analysis for expression of mitosis-related proteins

Cellular proteins were extracted, quantified, and subjected to gel electrophoresis. Protein samples were then blotted onto a polyvinylidene difluoride membrane. Primary antibodies against various proteins were used at various dilutions and detected by using horseradish peroxidase-conjugated anti-mouse immunoglobulin G followed by the use of enhanced chemiluminescence kits (Amersham Pharmacia Biotech). GAPDH expression was used as an internal control.

Costunolide treatment and radiation delivery

Cells were plated onto culture dishes to allow grow in DMEM medium contained 10% FCS mixed with various concentrations of costunolide for 4 hours. Then costunolide was washed out and the cells were irradiated with various doses. Radiation therapy with 6 MeV electron beam energy was delivered by a linear accelerator (Clinac 1800, Varian Associates, Inc., Palo Alto, CA, USA) with dose rate 2.4 Gy/min at various dose (0, 0.5, 1, 2 and 3 Gy) in a single fraction. The selection of radiation doses depended on our preliminary work on calibration of radiation survival curves of HA22T/VGH cells to ensure adequate coverage from 100% to less than 37% survival (D0 in radiobiology) for further estimation of surviving fraction. To fit the clinical relevance, 2 Gy was also selected to match the daily fraction size commonly used in clinical practice. Full electron equilibrium was ensured for each fraction by a parallel plate PR-60C ionization chamber (CAPINTEL, Inc., Ramsey, NY, USA). After radiation, cells were plated for clonogenic assay.

Clonogenic assay and estimation of SER

Viable tumor cells (103) were plated into each 35-mm culture dish and allowed to grow in DMEM containing 10% FCS. After 10 -14 days, the culture dishes were stained with 3% crystal violet and the numbers of colony (more than 50 cells) were counted. The mean control plating efficiency for untreated HA22T/VGH HCC cells was around 43%. The surviving fraction was calculated as mean colonies/cells inoculated. Survival curves were fitted by a linear-quadratic model. The sensitizer enhancement ratio (SER) was calculated as the radiation dose needed for radiation alone divided by the dose needed for various concentrations of costunolide plus radiation at a survival fraction of 37% (D0 in radiobiology).

Statistics

Data were presented as mean ± standard error from at least three experiments. IC50 values were calculated by GraphPad Prism 4 software (GraphPad Software, San Diego, California, USA). Statistical comparisons were made by using Student's t-test or one-way analysis of variance (ANOVA) as indicated. The difference was considered significant at p < 0.05. All data analysis was performed by using SPSS software (version 10.0, Chicago, IL, USA). We used Sigma Plot software (version 8.0, SPSS Inc., Chicago, IL, USA) with written syntax to fit survival curves with linear quadratic model.

Results

Cell viability and estimation of IC50

As demonstrated in Figure 1A, costunolide inhibited the viability of HA22T/VGH HCC cells in a concentration- and time-dependent manner. The estimated value of 50% inhibition concentration (IC50) was 4.7 μM. To sensitize tumor cell to radiation at a concentration range not extensively cytotoxic, costunolide at and below 5 μM was used for further cell cycle analysis and radiosensitizing experiments. Costunolide has no significant toxicity to normal human macrophages under the same experimental condition for HCC cells (Figure 1B).

Figure 1
figure 1

Growth inhibition in hepatoma cells and human normal macrophages treated by costunolide. Cell viability was assessed by trypan blue exclusion test for HA22T/VGH cells and MTT assay for macrophages. A, HA22T/VGH cells. B, Macrophages.

Full size image

Cell cycle analysis by DNA histogram

After 5 μM costunolide treatment for 0, 2, 4, 16 and 24 hours, the percentage of G2/M increased up to a high level at 4 h (34.8 ± 0.5%), indicating a rapid G2/M arresting activity (Table 1, Figure 2). It was accompanied by slight incline of S phase and marked decline of G0/G1 phase (Table 1, Figure 2).

Table 1 The cell cycle distribution, phosphorylated H3-positive rates and mitotic index of HA22T/VGH cells after costunolide treatment
Full size table
Figure 2
figure 2

Cell cycle analysis for HA22T/VGH cells treated by costunolide. Cells were treated with costunolide (5 μM for various time periods as indicated). Representative DNA histograms were demonstrated.

Full size image

Discrimination of mitosis arrest, other than G2 phase

To determine whether costunolide induced cell cycle arrest specifically at mitosis or G2 phase, we examined the phosphorylation status of histone H3 (Ser 10) and mitotic index, the hall markers of mitosis. By using nocodazole as a positive control (data not shown), the fluorocytometric assessment revealed a markedly corresponding increase in the percentage of phosphorylated histone H3-positive cells after costunolide treatment (Table 1, Figure 3). Mitotic index determined by morphological changes showed a similar pattern of changes (Table 1, Figure 4A). These results indicated that treatment with costunolide caused an arrest at mitosis, but not G2, phase in human hepatoma HA22T/VGH cells.

Figure 3
figure 3

Flow cytometric analysis for expression of phosphorylated histone H3 (Ser 10) in costunolide-treated HA22T/VGH cells. Cells were treated with costunolide (5 μM for various time periods as indicated). Representative dot-plot visuals were demonstrated.

Full size image
Figure 4
figure 4

Morphology of HA22T/VGH cells treated by 5 μM costunolide for 4 h. A. Liu's stain; B. Immunofluorescence stain for alpha-tubulin. Magnification: ×1000.

Full size image

Immunofluorescent stain for mitotic spindle

There are four stages in the mitotic phase. Immunofluorescent staining with alpha-tubulin was used to identify the cells located at which stage during the mitotic phase. In Figure 4B, the majority of the mitotic cells exhibited microtubule capture at both kinetochores of a duplicated chromatid pair which aligned in the center of the nucleus. The duplicated chromosome pairs were not separated apart and, instead, aggregated in the center of the nucleus in a round cell contour. These findings indicated a mitotic arrest at the metaphase was induced by costunolide.

Signaling molecules associated with mitosis arrest

As demonstrated in Figure 5, costunolide up-regulated the expression of phosphorylated Chk2 (Thr 68) up to 1.3 folds, phosphorylated Cdc25c (Ser 216) up to 1.3 folds, phosphorylated Cdk1 (Tyr 15) up to 1.3 folds and cyclin B1 up to 1.4 folds in HA22T/VGH cells. All these changes were greatest at 4 hours after costunolide treatment. No significant change was noted in the expression of phosphorylated Chk1 (Ser 317).

Figure 5
figure 5

The expression of mitosis arrest-related proteins after costunolide treatment in hepatoma cells. Lane 1, untreated control; lane 2 - 6, treated with 5 μM costunolide for various time points.

Full size image

Clonogenic survival and radiosensitization assessment

At the effective condition causing mitotic arrest, costunolide at 2.5 and 5 μM sensitized HA22T/VGH HCC cells to ionizing radiation with SERs up to 1.3 and 1.9, respectively (Figure 6A). For another hepatoma cell line, costunolide inhibited the radiation survival of Sk-Hep1 cells in a way resembling HA22T cells. The SERs for Sk-Hep1 was up to 1.5 at 5 μM of costunolide (Figure 6B).

Figure 6
figure 6

Costunolide enhances the radiosensitivity of hepatoma cells. A, HA22T/VGH cells. B, Sk-Hep1 cells. Clonogenic assay was used to estimate the survival of hepatoma cells.

Full size image

Discussion

Several novel radiosensitizers have been isolated from natural products via various kinds of pathways. In comparison to paclitaxel, a known spindle poison with radiosensitizing activity, costunolide pretreatment resulted in a similar SER at a less toxic concentration to cells. The parthenolide enhanced the radiation sensitivity of p53 null PC-3 cells by a dose modification factor of 1.7 [21]. Caffeic acid phenethyl ester, isolated from bee propolis, possesses a SER of 2.2 for rectal adenocarcinoma CT26 cells [22]. In general, SER values around 2.0 are acceptable for development of radiosensitizers.

The relationship between cell cycle and radiosensitization effect [23] has been extensively investigated. Both G2 and M phases were identified as radiosensitive phases. Moreover, cells at M phase were proven to be more sensitive to radiation than those at G2 phase [24–26]. Based on the data from phosphorylation status of histone H3, mitotic index and alpha-tubulin immunofluorescence stain, we specified that costunolide caused mitotic arrest at or close to metaphase, but not G2 phase. This mitosis-arresting activity might be further referred to the radiosensitizing effect of costinolide on hepatoma cells as we demonstrated in the present study.

Costunolide up-regulated the expression of phosphorylated Chk2 (Thr 68), phosphorylated Cdc25c (Ser 216), phosphorylated Cdk1 (Tyr 15) and cyclin B1 in HA22T/VGH cells. It is known that activated Chk2 could prevent mitotic progression by phosphorylating Cdc25C at Ser216, enhancing Cdc25C-14-3-3 binding to sequester Cdc25C in the cytoplasm and preventing dephosphorylation of Cdk1 (Tyr 15 or Thr 14) to inhibit the mitotic progression [27]. Thus, this modulation of Chk2/Cdc25c/Cdk1/cyclin B1 signaling by costunolide may contribute to the mitotic arrest in HA22T/VGH cells.

Given that costunolide is a naturally occurring compound with great quantity in wood Michelia compressa and other plants, unravel of this novel bioactivity for radiosensitization may shed a light in development of new pharmaceutical agents from agricultural products by using this experimental model.

In conclusion, costunolide specifically arrests cell cycle at mitosis accompanied by modulation of Chk2/Cdc25c/Cdk1/cyclin B1 signaling and enhancement of radioresponse in human hepatoma HA22T/VGH cells. Further studies of its effect on both hepatoma and normal liver counterpart by experimental animal model should be performed before consideration in clinical trial.

References

  1. Liu CY, Chen YW, Cheng MJ, Lee SJ, Abd El-Razek MH, Chang WH, Chen YJ, Chen IS: Cytotoxic constituents from the root wood of formosan Michelia compressa. J Chil Chem Soc 2008, 53: 1523-1524.

    Article  CAS  Google Scholar 

  2. Pandey MM, Rastogi S, Rawat AK: Saussurea costus: botanical, chemical and pharmacological review of an ayurvedic medicinal plant. J Ethnopharmacol 2007, 110: 379-390. 10.1016/j.jep.2006.12.033

    Article  CAS  PubMed  Google Scholar 

  3. Li A, Sun A, Liu R: Preparative isolation and purification of costunolide and dehydrocostuslactone from Aucklandia lappa Decne by high-speed counter-current chromatography. J Chromatogr A 2005, 1076: 193-197. 10.1016/j.chroma.2005.04.042

    Article  CAS  PubMed  Google Scholar 

  4. De Marino S, Borbone N, Zollo F, Ianaro A, Di Meglio P, Iorizzi M: New sesquiterpene lactones from Laurus nobilis leaves as inhibitors of nitric oxide production. Planta Med 2005, 71: 706-710. 10.1055/s-2005-864191

    Article  CAS  PubMed  Google Scholar 

  5. Koo TH, Lee JH, Park YJ, Hong YS, Kim HS, Kim KW, Lee JJ: A sesquiterpene lactone, costunolide, from Magnolia grandiflora inhibits NF-kappa B by targeting I kappa B phosphorylation. Planta Med 2001, 67: 103-107. 10.1055/s-2001-11503

    Article  CAS  PubMed  Google Scholar 

  6. Mondranondra IO, Che CT, Rimando AM, Vajrodaya S, Fong HH, Farnsworth NR: Sesquiterpene lactones and other constituents from a cytotoxic extract of Michelia floribunda. Pharm Res 1990, 7: 1269-1272. 10.1023/A:1015937921880

    Article  CAS  PubMed  Google Scholar 

  7. Bocca C, Gabriel L, Bozzo F, Miglietta A: A sesquiterpene lactone, costunolide, interacts with microtubule protein and inhibits the growth of MCF-7 cells. Chem Bio Interacti 2004, 147: 79-86. 10.1016/j.cbi.2003.10.008

    Article  CAS  Google Scholar 

  8. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009, 59: 225-249. 10.3322/caac.20006

    Article  PubMed  Google Scholar 

  9. Hertl M, Cosimi AB: Liver transplantation for malignancy. Oncologist 2005, 10: 269-281. 10.1634/theoncologist.10-4-269

    Article  PubMed  Google Scholar 

  10. Poon RT, Fan ST, Lo CM, Liu CL, Wong J: Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 1999, 229: 216-222. 10.1097/00000658-199902000-00009

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Yamamoto J, Kosuge T, Takayama T, Shimada K, Yamasaki S, Ozaki H, Yamaguchi N, Makuuchi M: Recurrence of hepatocellular carcinoma after surgery. Br J Surg 1996, 83: 1219-1222. 10.1002/bjs.1800830913

    Article  CAS  PubMed  Google Scholar 

  12. Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, Lenoir C, Attali P, Etienne JP: A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990, 11: 181-184. 10.1016/0168-8278(90)90110-D

    Article  CAS  PubMed  Google Scholar 

  13. Lau WY, Lai EC: The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg 2009, 249: 20-25. 10.1097/SLA.0b013e31818eec29

    Article  PubMed  Google Scholar 

  14. Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, Choi JY, Yoon SK, Chung KW: Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 2010, 10: 475. 10.1186/1471-2407-10-475

    Article  PubMed Central  PubMed  Google Scholar 

  15. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al.: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10: 25-34. 10.1016/S1470-2045(08)70285-7

    Article  CAS  PubMed  Google Scholar 

  16. Seong J, Han KH, Park YN, Nam SH, Kim SH, Keum WS, Kim KS: Lethal hepatic injury by combined treatment of radiation plus chemotherapy in rats with thioacetamide-induced liver cirrhosis. Int J Radiat Oncol Biol Phys 2003, 57: 282-288. 10.1016/S0360-3016(03)00540-6

    Article  PubMed  Google Scholar 

  17. Park HC, Seong J, Han KH, Chon CY, Moon YM, Suh CO: Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2002, 54: 150-155.

    Article  PubMed  Google Scholar 

  18. Milross CG, Mason KA, Hunter NR, Terry NH, Patel N, Harada S, Jibu T, Seong J, Milas L: Enhanced radioresponse of paclitaxel-sensitive and -resistant tumours in vivo. Eur J Cancer 1997, 33: 1299-1308. 10.1016/S0959-8049(97)00107-X

    Article  CAS  PubMed  Google Scholar 

  19. Choy H, Rodriguez FF, Koester S, Hilsenbeck S, Von Hoff DD: Investigation of taxol as a potential radiation sensitizer. Cancer 1993, 71: 3774-3778. 10.1002/1097-0142(19930601)71:11<3774::AID-CNCR2820711147>3.0.CO;2-0

    Article  CAS  PubMed  Google Scholar 

  20. Liu X, Guo Y, Li Y, Jiang Y, Chubb S, Azuma A, Huang P, Matsuda A, Hittelman W, Plunkett W: Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation. Cancer Res 2005, 65: 6874-6881. 10.1158/0008-5472.CAN-05-0288

    Article  CAS  PubMed  Google Scholar 

  21. Watson C, Miller DA, Chin-Sinex H, Losch A, Hughes W, Sweeney C, Mendonca MS: Suppression of NF-kappaB activity by parthenolide induces X-ray sensitivity through inhibition of split-dose repair in TP53 null prostate cancer cells. Radiat Res 2009, 171: 389-396. 10.1667/RR1394.1

    Article  CAS  PubMed  Google Scholar 

  22. Chen YJ, Liao HF, Tsai TH, Wang SY, Shiao MS: Caffeic acid phenethyl ester preferentially sensitizes CT26 colorectal adenocarcinoma to ionizing radiation without affecting bone marrow radioresponse. Int J Radiat Oncol Biol Phys 2005, 63: 1252-1261. 10.1016/j.ijrobp.2005.08.001

    Article  CAS  PubMed  Google Scholar 

  23. Pawlik TM, Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004, 59: 928-942. 10.1016/j.ijrobp.2004.03.005

    Article  PubMed  Google Scholar 

  24. Terasima T, Tolmach LJ: X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells. Science 1963, 140: 490-492. 10.1126/science.140.3566.490

    Article  CAS  PubMed  Google Scholar 

  25. Sinclair WK: Cyclic x-ray responses in mammalian cells in vitro. Radiat Res 1968, 33: 620-643. 10.2307/3572419

    Article  CAS  PubMed  Google Scholar 

  26. Sinclair WK, Morton RA: X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 1966, 29: 450-474. 10.2307/3572025

    Article  CAS  PubMed  Google Scholar 

  27. Schmit TL, Ahmad N: Regulation of mitosis via mitotic kinases: new opportunities for cancer management. Mol Cancer Ther 2007, 6: 1920-1931. 10.1158/1535-7163.MCT-06-0781

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan

    Chia-Yuan Liu, Shu-Ling Fu & Yu-Jen Chen

  2. Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan

    Ming-Ling Hsu & Yu-Jen Chen

  3. Section of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan

    Chia-Yuan Liu & Chih-Jen Chen

  4. Department of Radiation Oncology, Mackay Memorial Hospital, Taipei, Taiwan

    Yu-Jen Chen

  5. Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan

    Hsun-Shuo Chang & Ih-Sheng Chen

Authors
  1. Chia-Yuan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hsun-Shuo Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ih-Sheng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chih-Jen Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ming-Ling Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shu-Ling Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yu-Jen Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Shu-Ling Fu or Yu-Jen Chen.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

CYL participated in the design of the study and performed the cell cycle analysis and radiosensitivity experiment. HSC and ISC both purified chemical compound constunolide. CJC participated in its design and coordination of manuscript. MLH performed the expression of protein assay. YJC and SLF both conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Authors’ original submitted files for images

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Liu, CY., Chang, HS., Chen, IS. et al. Costunolide causes mitotic arrest and enhances radiosensitivity in human hepatocellular carcinoma cells. Radiat Oncol 6, 56 (2011). https://doi.org/10.1186/1748-717X-6-56

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/1748-717X-6-56

Keywords

Radiation Oncology

ISSN: 1748-717X

Contact us